Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Begbies Traynor to beat market forecasts after strong end to year

(Sharecast News) - Shares in Begbies Traynor were rising on Friday after the business recovery and financial advisory firm reported a strong end to its financial year, with revenues, profits and cash ahead of market forecasts. Revenues over the year to 30 April were £153m, up 12% on the previous year and ahead of the company-compiled consensus forecast of £152.1m.

Results were driven by higher insolvency activity levels in higher value cases, strong growth in advisory income, and a good performance in property advisory and transactional services.

Adjusted EBITDA increased 10% year-on-year to £31.3m, ahead of the £30.5m estimate, while net cash was £0.9m by the end of the year, compared with expectations that net debt would swell to £2.6m from £1.4m.

"The group has delivered double digit revenue and EBITDA growth, ahead of consensus expectations, marking its tenth successive year of profit growth," said executive chair Ric Traynor.

"This reflects strong demand across the breadth of the group's services - from insolvency through to complex restructuring and our broad range of complementary financial and real estate advisory services."

Shares were up 3.1% at 101p by 0827 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.